Skip to main content
SpringerLink
Log in

Vaccines Against Bacterial Endotoxins

  • Chapter
The Sepsis Text

  • 327 Accesses

Conclusion

The use of vaccines that induce antibodies to either highly conserved epitopes in the LPS core or to serotype-specific antigens (O-polysaccharide or CPS) remains a viable strategy for the prevention and/or treatment of sepsis. Unfortunately, despite decades of intensive efforts, there is little data that demonstrates a consistent clinical benefit from this vaccine approach. The potential pitfalls are many: developing a relatively non-toxic, reproducible vaccine that is sufficiently immunogenic that it can induce antibodies in a reasonably rapid period of time and in the target (i.e., immunocompromised or trauma patients) patient populations; in the case of anti-core LPS antibodies, identifying critical epitopes to which the antibodies may bind; demonstrating a mechanism of action that would also permit clinicians to monitor patient risk and/or vaccine efficacy (short of mortality). Even if these concerns are satisfied, the antibodies must be delivered and maintained in sufficient amounts such that there is not consumption of antibody below those levels necessary for successful therapy. This latter consideration has not been given sufficient attention in clinical trials reported to date.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rangel-Frausto SM. The epidemiology of bacterial sepsis. Infect Dis Clin North Am 1999; 13:299–312

    PubMed  CAS  Google Scholar 

  2. Wenzel RP. The mortality of hospital-acquired bloodstream infections: Need for a new vital statistic? Int J Epidemiol 1988; 17:225–227

    PubMed  CAS  Google Scholar 

  3. Parillo JE, Parker MM, Natanson C. Septic shock in humans. Ann Intern Med 1990; 113:227–242

    Google Scholar 

  4. Suffredini AF, Forman RE, Parker MM. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321:280–287

    Article  PubMed  CAS  Google Scholar 

  5. Bauer RJ, Wedel N, Havrilla N, et al. Pharmacokinetics of a recombinant modified amino terminal fragment of bactericidal/permeability-increasing protein (rBPI21) in healthy volunteers. J Clin Pharmacol 1999; 39:1169–1176

    PubMed  CAS  Google Scholar 

  6. Weiner DL, Kuppermann N, Saladino RA, et al. Comparison of early and late treatment with a recombinant endotoxin neutralizing protein in a rat model of Escherichia coli sepsis. CritCareMed 1996; 24:1514–1517

    CAS  Google Scholar 

  7. Drabick JJ, Bhattacharjee AK, Hoover DL, et al. Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent. Antimicrob Agents Chemother 1998; 42:583–588

    PubMed  CAS  Google Scholar 

  8. Fletcher MA, Kloczewiak MA, Loiselle PM, et al. A novel peptide-IgG conjugate, CAP18(106–138)-IgG, that binds and neutralizes endotoxin and kills gram-negative bacteria. J Infect Dis 1997; 175:621–632

    PubMed  CAS  Google Scholar 

  9. Ziegler EJ, Fisher CJJ, Sprung CL, et al. Treatment of gram-negative bacteremia in septic shock with HA1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 325:429–436

    Google Scholar 

  10. Bone RC, Balk RA, Fein AM. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23:994–1006

    PubMed  CAS  Google Scholar 

  11. Bhattacharjee AK, Cross AS. Vaccines and antibodies in the prevention and treatment of sepsis. Infect Dis Clin North Am 1999; 13:355–369

    Article  PubMed  CAS  Google Scholar 

  12. Hellman J, Warren HS. Endotoxin Strategies. Infect Dis Clin North Am 1999; 13:373–386

    Article  Google Scholar 

  13. Verhoef J, Hustinx WMN, Frasa H, et al. Issues in the adjunct therapy of severe sepsis. J Antimicrob Chemother 1996; 38:167–182

    PubMed  CAS  Google Scholar 

  14. Lynn WA. Anti-endotoxin therapeutic options for the treatment of sepsis. J Antimicrob Chemother 1998; 41:71–80

    Article  PubMed  CAS  Google Scholar 

  15. Raetz CRH. Biochemistry of endotoxins. Annu Rev Biochem 1990; 59:129–170

    Article  PubMed  CAS  Google Scholar 

  16. Raetz CRH, Ulevitch RJ, Wright SD, et al. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 1991; 5:2652–2660

    PubMed  CAS  Google Scholar 

  17. Kenne L, Lindberg B. Bacterial polysaccharides. In: Aspinall GO (ed) Polysaccharides. Vol. 2. Academic Press, New York 1983, pp:287–364

    Google Scholar 

  18. Holst O, Brade H. Chemical structure of the core region of lipopolysaccharides. In: Morrison DC, Ryan JL (eds) Bacterial Endotoxic Lipopolysaccharides: Molecular Biochemistry and Cellular Biology. Vol I. CRC Press, Boca Raton 1992, pp:135–152

    Google Scholar 

  19. Braude Al, Douglas H. Passive immunization against the local Shwartzman reaction. J Immunol 1972; 108:505–512

    PubMed  CAS  Google Scholar 

  20. McCabe WR, Greely A. Immunization with R mutants of S. minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol 1972; 108:601–610

    PubMed  CAS  Google Scholar 

  21. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:1225–1230

    Article  PubMed  CAS  Google Scholar 

  22. Calandra T, Glauser MP, Schellekens J, et al. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 1988; 158:312–319

    PubMed  CAS  Google Scholar 

  23. Bhattacharjee AK, Opal SM, Palardy JE, et al. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against Gram-negative bacterial sepsis. J Infect Dis 1994; 170:622–629

    PubMed  CAS  Google Scholar 

  24. Bhattacharjee AK, Opal SM, Taylor R, et al. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against Gram-negative bacteremia. J Infect Dis 1996; 173:1157–1163

    PubMed  CAS  Google Scholar 

  25. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:1–5

    PubMed  CAS  Google Scholar 

  26. Bone RC, Balk RS, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23:994–1006

    PubMed  CAS  Google Scholar 

  27. Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 1992; 326:1153–1157

    Article  PubMed  CAS  Google Scholar 

  28. Galanos C, Freudenberg MA, Jay F, et al. Immunogenic properties of lipid A. Rev Infect Dis 1984; 6:546–552

    PubMed  CAS  Google Scholar 

  29. Brade L, Engel R, Christ WJ, et al. A nonsubstituted primary hydroxyl group in position 6′ of free lipid A is required for binding of lipid A monoclonal antibodies. Infect Immun 1997;65:3961–3965

    PubMed  CAS  Google Scholar 

  30. Lugowski C, Jachymek W, Niedziela T, et al. Serological characterization of anti-endotoxin sera directed against the conjugates of oligosaccharide core of Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid. FEMS Immunol Med Microbiol 1996; 16:21–30

    PubMed  CAS  Google Scholar 

  31. Lugowski C, Niedziela T, Jachymek W. Anti-endotoxin antibodies directed against Escherichia coli Rl oligosaccharide core-tetanus toxoid conjugate bind to smooth live bacteria and smooth lipopolysaccharides and attenuate their tumor necrosis factor stimulating activity. FEMS Immunol Med Microbiol 1996; 16:31–38

    PubMed  CAS  Google Scholar 

  32. Stanislavsky ES, Makarenko TA, Kholodkova EV, et al. R-form lipopolysaccharides (LPS) of gram-negative bacteria as possible vaccine antigens. FEMS Immunol Med Microbiol 1997; 18:139–145

    Article  PubMed  CAS  Google Scholar 

  33. Lugowski C, Czaja J, Jachymek W, Niedziela T, Lakomska J. Serological characterization of anti-endotoxin serum directed against the conjugate of oligosaccharide core of Escherichia coli type R4 with tetanus toxoid. J Endotoxin Res 2000; 6:166 (Abst)

    Google Scholar 

  34. Bennett-Guerrero, E, Mclntosh TJ, Barclay GR, et al. Preparation and preclinical evaluation of a novel complete core LPS vaccine. J Endotoxin Res 2000; 6:168 (Abst)

    Google Scholar 

  35. Eldridge C, Stewart J, Bennett-Guerrero E, Poxton IR. The biological activity of a liposomal complete core LPS vaccine. J Endotoxin Res 2000; 6:133 (Abst)

    Google Scholar 

  36. Griesman SE, Johnson CA. Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during Gram-negtive bacterial sepsis. J Endotox Res 1997; 4:123–153

    Google Scholar 

  37. Cross AS, Opal SM, Bhattacharjee AK, et al. Immunotherapy of sepsis: flawed concept or faulty implementation. Vaccine 1999; 17:S13–S21

    Article  PubMed  Google Scholar 

  38. Nnalue NA, Lind SM, Lindberg AA. The disaccharide L-a-D-heptose 1-7-L-a-D-heptose 1-of the inner core domain of Salmonella lipopolysaccharide is accessible to antibody and is the epitope of a broadly reactive monoclonal antibody. J Immunol 1992; 149:2722–2728

    PubMed  CAS  Google Scholar 

  39. Nnalue NA. α-GlcNAc-1-2-α-Glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies. Infect Immun 1998; 66:4389–4396

    PubMed  CAS  Google Scholar 

  40. Di Padova FE, Brade H, Barclay GR, et al. A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect. Immun. 1993;61:3863–3872

    PubMed  Google Scholar 

  41. Bailat S, Heuman D, Le Roy D, et al. Similarities and disparities between core-specific and O-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice. Infect Immun 1997; 65:811–814

    PubMed  CAS  Google Scholar 

  42. Cross AS, Opal SM, Warren HS, et al. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J Infect Dis 2001; 183:1079–1086

    Article  PubMed  CAS  Google Scholar 

  43. Cryz SJJ, Lang AB, Sadoff JC, et al. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect Immun 1987; 55:1547–1551

    PubMed  CAS  Google Scholar 

  44. Cross AS, Artenstein A, Que JO, et al. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis 1994; 170:834–840

    PubMed  CAS  Google Scholar 

  45. Edelman R, Taylor DN, Wasserman SS, et al. Phase I trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an 8-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Vaccine 1994; 12:1288–1294

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Apurba K. Bhattacharjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan S. Cross
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven M. Opal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care, Erasme University Hospital, Brussels, Belgium

    Jean-Louis Vincent M.D.

  2. Service de Réanimation Polyvalente, Hôpital Saint-Joseph, Paris, France

    Jean Carlet M.D.

  3. Division of Infectious Diseases, The Memorial Hospital of Rhode Island, Pawtucket, RI

    Steven M. Opal M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic Publishers

About this chapter

Cite this chapter

Bhattacharjee, A.K., Cross, A.S., Opal, S.M. (2002). Vaccines Against Bacterial Endotoxins. In: Vincent, JL., Carlet, J., Opal, S.M. (eds) The Sepsis Text. Springer, Boston, MA. https://doi.org/10.1007/0-306-47664-9_49

Download citation

  • DOI: https://doi.org/10.1007/0-306-47664-9_49

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-7923-7620-0

  • Online ISBN: 978-0-306-47664-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation